155 related articles for article (PubMed ID: 35775783)
1. Use of MicroRNAs as biomarkers in the early diagnosis of prostate cancer.
Canatan D; Yılmaz O; Sonmez Y; Cim A; Baykara M; Savas M; Coskun HS; Goksu SS; Aktekin MR
Acta Biomed; 2022 Jul; 93(3):e2022089. PubMed ID: 35775783
[TBL] [Abstract][Full Text] [Related]
2. Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.
Porzycki P; Ciszkowicz E; Semik M; Tyrka M
Int Urol Nephrol; 2018 Sep; 50(9):1619-1626. PubMed ID: 30014459
[TBL] [Abstract][Full Text] [Related]
3. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method.
Xu Y; Qin S; An T; Tang Y; Huang Y; Zheng L
Prostate; 2017 Jul; 77(10):1167-1175. PubMed ID: 28617988
[TBL] [Abstract][Full Text] [Related]
4. Semen miRNAs Contained in Exosomes as Non-Invasive Biomarkers for Prostate Cancer Diagnosis.
Barceló M; Castells M; Bassas L; Vigués F; Larriba S
Sci Rep; 2019 Sep; 9(1):13772. PubMed ID: 31551516
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer early diagnosis: circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples.
Liu HP; Lai HM; Guo Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32607548
[TBL] [Abstract][Full Text] [Related]
6. Expression Analysis of miRNAs and Their Potential Role as Biomarkers for Prostate Cancer Detection.
Bergez-Hernández F; Arámbula-Meraz E; Alvarez-Arrazola M; Irigoyen-Arredondo M; Luque-Ortega F; Martínez-Camberos A; Cedano-Prieto D; Contreras-Gutiérrez J; Martínez-Valenzuela C; García-Magallanes N
Am J Mens Health; 2022; 16(5):15579883221120989. PubMed ID: 36082407
[TBL] [Abstract][Full Text] [Related]
7. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
8. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
Stephan C; Jung M; Rabenhorst S; Kilic E; Jung K
Clin Chem Lab Med; 2015 Jun; 53(7):1109-18. PubMed ID: 25720086
[TBL] [Abstract][Full Text] [Related]
9. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer.
McDonald AC; Vira M; Shen J; Sanda M; Raman JD; Liao J; Patil D; Taioli E
Prostate; 2018 May; 78(6):411-418. PubMed ID: 29383739
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
12. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
13. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone.
Kang HW; Byun YJ; Moon SM; Kim K; Piao XM; Zheng CM; Moon SK; Choi YH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2022 Mar; 63(2):238-244. PubMed ID: 35244999
[TBL] [Abstract][Full Text] [Related]
14. The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p.
Tölle A; Jung K; Friedersdorff F; Maxeiner A; Lein M; Fendler A; Stephan C
Cancer Biomark; 2021; 30(4):381-393. PubMed ID: 33361585
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
16. Detection of miRNAs in urine of prostate cancer patients.
Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
[TBL] [Abstract][Full Text] [Related]
17. DNA-gold nanoprobe-based integrated biosensing technology for non-invasive liquid biopsy of serum miRNA: A new frontier in prostate cancer diagnosis.
Kshirsagar P; Seshacharyulu P; Muniyan S; Rachagani S; Smith LM; Thompson C; Shah A; Mallya K; Kumar S; Jain M; Batra SK
Nanomedicine; 2022 Jul; 43():102566. PubMed ID: 35569810
[TBL] [Abstract][Full Text] [Related]
18. A circulating miRNA assay as a first-line test for prostate cancer screening.
Sharova E; Grassi A; Marcer A; Ruggero K; Pinto F; Bassi P; Zanovello P; Zattoni F; D'Agostino DM; Iafrate M; Ciminale V
Br J Cancer; 2016 Jun; 114(12):1362-6. PubMed ID: 27228285
[TBL] [Abstract][Full Text] [Related]
19. Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer.
Kotb S; Mosharafa A; Essawi M; Hassan H; Meshref A; Morsy A
Tumour Biol; 2014 Dec; 35(12):12613-7. PubMed ID: 25190021
[TBL] [Abstract][Full Text] [Related]
20. MiR-139-5p is Increased in the Peripheral Blood of Patients with Prostate Cancer.
Pang C; Liu M; Fang W; Guo J; Zhang Z; Wu P; Zhang Y; Wang J
Cell Physiol Biochem; 2016; 39(3):1111-7. PubMed ID: 27562849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
